clinical trial

June 24, 2016June 24, 2016

Novartis Trial Assesses Ultibro Breezhaler For COPD Flare-Ups

COPD, News

Novartis recently announced encouraging data from a clinical trial evalutating the efficacy of once-daily Ultibro Breezhaler (indacaterol/glycopyrronium bromide) for reducing chronic obstructive pulmonary disease (COPD) flare-ups. The report was published in the New England ... Read more

June 23, 2016June 23, 2016

Phase 2 Study of Hemoglobin Modifier, GBT440, to Treat IPF Getting Underway

Idiopathic Pulmonary Fibrosis, News

Global Blood Therapeutics (GBT) is starting a Phase 2a clinical trial to assess the company’s lead product, GBT440, as a treatment for adults with idiopathic pulmonary fibrosis (IPF) and hypoxemia. GBT440 is ... Read more

June 22, 2016June 22, 2016

INOpulse Devices for PAH Disorders Evaluated in Clinical Trials

COPD, Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

Bellerophon Therapeutics recently enrolled the first participants in the Phase 3 INOvation-1 clinical trial intended to test the efficiency and safety of INOpulse for the treatment of pulmonary arterial hypertension (PAH). ... Read more

June 13, 2016June 13, 2016

Drug for Cystic Fibrosis, Other Lung Diseases Reaches Successful Phase 1 End

News

Polyphor, a Swiss pharmaceutical focused on macrocycle drug discovery and development, recently announced the successful conclusion of its Phase 1 clinical testing of POL6014 for cystic fibrosis (CF), Alpha-1 Antitrypsin Deficiency (AATD), and other lung diseases. ... Read more

May 27, 2016May 27, 2016

Phase 2 Trial for Oral Cystic Fibrosis Treatment Gets Canada’s Green Light

Cystic Fibrosis, News

The Canadian biopharmeceutical corporation ProMetic Life Sciences has been authorized by Health Canada to begin a study on PBI-4050, its orally active anti-fibrotic investigational drug for the treatment of cystic fibrosis (CF). ... Read more

May 24, 2016May 24, 2016

First Patient Dosed in Phase 2 Trial of Potential CF Treatment

Cystic Fibrosis, News

Nivalis Therapeutics, Inc., announced the first dosing of a cystic fibrosis (CF) patient enrolled in its second Phase 2 clinical trial evaluating the drug N91115, a stabilizer of the cystic fibrosis transmembrane conductance regulator ... Read more

May 24, 2016May 24, 2016

Bayer Ends Phase 2 Trial of Riociguat in PH Patients with Idiopathic Interstitial Pneumonias

News, Pulmonary Hypertension

Bayer has stopped a Phase 2 clinical trial (NCT02138825) evaluating riociguat (Adempas) in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP) on the recommendation of the study’s Data Monitoring Committee (DMC). The committee — sometimes ... Read more

May 19, 2016May 19, 2016

Phase 3 Drug Improves Lung Function for COPD Patients with Symptoms After Tiotropium

COPD, News

A new phase 3 clinical study conducted by GSK and Innoviva, Inc. shows that Anoro Ellipta significantly improves lung function in people with COPD, compared to another drug called tiotropium.

May 3, 2016May 3, 2016

Cytori Updates Phase 3 Scleroderma STAR Trial, Enrolls 60th Patient

News, Scleroderma

Cell therapy company Cytori Therapeutics announced that its Phase 3 STAR clinical trial has enrolled and treated its 60th patient, reaching 75 percent of the target enrollment (80 patients). Safety data review ... Read more

April 18, 2016April 19, 2016

Karos Pharmaceuticals Advances PAH Drug Candidate into the Clinic

News, Pulmonary Hypertension

Karos Pharmaceuticals recently announced it has advanced its small molecule investigational drug candidate, KAR5585, into the clinic for the treatment of pulmonary arterial hypertension (PAH) and other rare conditions marked ... Read more